Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GDC-6036 + atezolizumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
GDC-6036 + atezolizumab is an investigational combination therapy evaluated in phase I/II clinical trials for the treatment of advanced or metastatic solid tumors harboring a KRAS G12C mutation, particularly non-small cell lung cancer. GDC-6036 is a selective small molecule inhibitor of KRAS G12C, while atezolizumab is a humanized monoclonal antibody targeting PD-L1, working as an immune checkpoint inhibitor. This regimen is being developed to harness the direct anti-tumor effect of KRAS G12C inhibition alongside the immune-stimulating effects of PD-L1 blockade to improve tumor response and clinical outcomes[1][3][4][5][7].
- Brand names
- Tecentriq
- Other names
- GDC-6036 plus atezolizumabGDC6036 plus atezolizumabGDC 6036 plus atezolizumabGDC-6036 and atezolizumabGDC6036 and atezolizumabGDC 6036 and atezolizumab
02
Targets
KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on GDC-6036 + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GDC-6036 + atezolizumab.